Sun Guangxia, Hao Wanming, Li Qinghai, Ma Yan, Sun Fenglan, Su Yi, Yu Xinjuan, Han Wei
Qingdao Municipal Hospital, Nanjing Medical University, Qingdao, China.
Department of Respiratory and Critical Care Medicine, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
Microbiol Spectr. 2025 Aug 5;13(8):e0196924. doi: 10.1128/spectrum.01969-24. Epub 2025 Jul 14.
The objective of this study was to investigate the therapeutic and prophylactic effects of the mixed extract of Staphylococcus and Neisseria tablets (Qipian) on chronic obstructive pulmonary disease (COPD) in mice and its relationship with lung and gut microbiota. C57BL/6 mice were divided into two models (prophylactic versus therapeutic administration). In the model of prophylactic administration, the mice were exposed to cigarette smoke (CS) for 16 weeks and divided into CS+Qipian group, CS+OM-85 group, and CS control group. Compared to the CS control group, mice in both CS+Qipian and CS+OM-85 groups had improved lung function, reduced pulmonary bullae and inflammatory cell infiltration, reduced collagen deposition around the bronchi, and decreased levels of inflammatory cytokines in the lung tissue. Qipian and OM-85 significantly increased the diversity of gut and lung microbiota and the abundance of Bacteroidetes, , and , as well as inhibited the toll-like receptor 4 (TLR4)/nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) pathway. There were no significant differences in the above parameters between the CS+OM-85 group and the CS+Qipian group. In the therapeutic administration model, the mice were exposed to CS for 24 weeks, and the results were consistent with those of the prophylactic administration model. Qipian administration has both preventive and therapeutic effects on COPD possibly by regulating the microbiota dysbiosis through the gut-lung axis, inhibiting the activation of the TLR4/NF-κB pathway, reducing inflammation, and improving lung function.IMPORTANCEGut and lung microbiota are associated with the development and progression of chronic obstructive pulmonary disease (COPD). Qipian treatment significantly increased the diversity of gut and lung microbiota and the abundance of Bacteroidetes, , and . In addition, the toll-like receptor 4/nuclear factor kappa-light-chain enhancer of activated B cells pathway mediated by the gut-lung axis may play an essential role in preventing and treating the pathogenesis of COPD, which allows for reduced inflammation and improvement of lung function.
本研究的目的是探讨葡萄球菌奈瑟菌片（七片）混合提取物对小鼠慢性阻塞性肺疾病（COPD）的治疗和预防作用及其与肺和肠道微生物群的关系。将C57BL/6小鼠分为两个模型（预防性给药与治疗性给药）。在预防性给药模型中，小鼠暴露于香烟烟雾（CS）16周，分为CS+七片组、CS+OM-85组和CS对照组。与CS对照组相比，CS+七片组和CS+OM-85组小鼠的肺功能均有所改善，肺大疱和炎性细胞浸润减少，支气管周围胶原沉积减少，肺组织中炎性细胞因子水平降低。七片和OM-85显著增加了肠道和肺微生物群的多样性以及拟杆菌属、、和的丰度，同时抑制了Toll样受体4（TLR4）/核因子κB（NF-κB）通路。CS+OM-85组和CS+七片组在上述参数上无显著差异。在治疗性给药模型中，小鼠暴露于CS 24周，结果与预防性给药模型一致。七片给药对COPD可能具有预防和治疗作用，其机制可能是通过肠-肺轴调节微生物群失调，抑制TLR4/NF-κB通路的激活，减轻炎症并改善肺功能。重要性肠道和肺微生物群与慢性阻塞性肺疾病（COPD）的发生和发展相关联。七片治疗显著增加了肠道和肺微生物群的多样性以及拟杆菌属、、和的丰度。此外，由肠-肺轴介导的Toll样受体4/核因子κB通路可能在预防和治疗COPD发病机制中起重要作用，从而减少炎症并改善肺功能。
